Profile data is unavailable for this security.
About the company
Zevra Therapeutics, Inc. is a rare disease company science, data, and patients need to create transformational therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical stage pipeline and commercial stage assets. Its pipeline includes arimoclomol, an orally delivered, investigational product candidate being developed for Niemann-Pick disease type C (NPC). KP1077 is the Company's lead clinical development product candidate which is being developed as a treatment for idiopathic hypersomnia (IH), a rare neurological sleep disorder, and narcolepsy. Its commercial product, AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder (ADHD), in patients aged six years and older containing its prodrug, serdexmethylphenidate (SDX), and d-methylphenidate (d-MPH). Its other commercial product is OLPRUVA.
- Revenue in USD (TTM)28.01m
- Net income in USD-50.90m
- Incorporated2014
- Employees65.00
- LocationZevra Therapeutics Inc1180 CELEBRATION BOULEVARD, SUITE 103CELEBRATION 34747United StatesUSA
- Phone+1 (321) 939-3416
- Fax+1 (319) 665-2577
- Websitehttps://zevra.com/
Mergers & acquisitions
Acquired company | ZVRA:NSQ since announced | Transaction value |
---|---|---|
Acer Therapeutics Inc | -12.26% | 91.00m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Capricor Therapeutics Inc | 27.10m | -24.31m | 180.69m | 101.00 | -- | 9.74 | -- | 6.67 | -0.8755 | -0.8755 | 0.9574 | 0.5834 | 0.5246 | -- | 59.13 | 268,299.50 | -47.07 | -54.12 | -122.20 | -75.13 | -- | -- | -89.72 | -316.25 | -- | -- | 0.1548 | -- | 886.81 | 72.02 | 23.20 | -- | 45.27 | -- |
Trevi Therapeutics Inc | 0.00 | -33.57m | 181.02m | 25.00 | -- | 2.45 | -- | -- | -0.338 | -0.338 | 0.00 | 1.05 | 0.00 | -- | -- | 0.00 | -34.47 | -47.39 | -38.08 | -54.41 | -- | -- | -- | -- | -- | -- | 0.0017 | -- | -- | -- | 0.2984 | -- | -2.81 | -- |
Fennec Pharmaceuticals Inc | 44.95m | 2.84m | 185.24m | 36.00 | 185.40 | 60.97 | 65.14 | 4.12 | 0.0366 | 0.0366 | 1.62 | 0.1112 | 0.9878 | 1.15 | 7.52 | -- | 6.25 | -73.43 | 7.37 | -84.32 | 96.19 | -- | 6.33 | -383.28 | 6.72 | 1.84 | 0.9087 | -- | 1,284.50 | -- | 32.34 | -- | -- | -- |
Puma Biotechnology Inc | 226.63m | 15.38m | 185.72m | 185.00 | 11.96 | 3.64 | 6.90 | 0.8195 | 0.3219 | 0.3219 | 4.74 | 1.06 | 1.10 | 10.95 | 8.13 | 1,225,016.00 | 7.49 | -12.21 | 11.65 | -20.53 | 73.44 | 78.78 | 6.78 | -11.79 | 1.38 | 2.57 | 0.6624 | -- | 3.34 | -1.25 | 1,079,450.00 | -- | 83.41 | -- |
INmune Bio Inc | 131.00k | -34.50m | 186.94m | 11.00 | -- | 5.84 | -- | 1,427.05 | -1.92 | -1.92 | 0.0073 | 1.62 | 0.0022 | -- | 0.0535 | 11,909.09 | -57.11 | -37.82 | -74.12 | -41.86 | -- | -- | -26,333.59 | -14,901.03 | -- | -16.97 | 0.2044 | -- | -58.56 | -- | -9.92 | -- | -- | -- |
Lineage Cell Therapeutics Inc | 8.00m | -23.66m | 188.82m | 75.00 | -- | 2.61 | -- | 23.59 | -0.1344 | -0.1344 | 0.0455 | 0.3836 | 0.0722 | -- | 57.16 | 106,706.70 | -21.32 | -19.53 | -24.82 | -22.59 | 91.88 | 89.13 | -295.30 | -370.88 | -- | -- | 0.0018 | -- | -39.16 | 12.39 | 18.22 | -- | -27.16 | -- |
Greenwich Lifesciences Inc | 0.00 | -9.24m | 191.01m | 3.00 | -- | 37.29 | -- | -- | -0.719 | -0.719 | 0.00 | 0.3977 | 0.00 | -- | -- | 0.00 | -106.03 | -36.43 | -109.97 | -38.31 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.63 | -- | -- | -- |
Compass Therapeutics Inc. | 0.00 | -45.44m | 194.00m | 32.00 | -- | 1.24 | -- | -- | -0.3513 | -0.3513 | 0.00 | 1.14 | 0.00 | -- | -- | 0.00 | -26.03 | -41.75 | -27.21 | -46.41 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.33 | -- | -56.91 | -- |
TriSalus Life Sciences Inc | 21.98m | -68.07m | 194.46m | 112.00 | -- | -- | -- | 8.85 | -2.09 | -2.09 | 0.7291 | -1.31 | 1.17 | 1.26 | 7.49 | 196,276.80 | -339.18 | -- | -11,196.50 | -- | 86.74 | -- | -291.08 | -- | 0.714 | -16.82 | -- | -- | 49.31 | -- | -26.51 | -- | -- | -- |
Zevra Therapeutics Inc | 28.01m | -50.90m | 194.62m | 65.00 | -- | 3.99 | -- | 6.95 | -1.34 | -1.34 | 0.7513 | 1.17 | 0.2172 | -- | 3.47 | 430,876.90 | -39.48 | -32.11 | -47.94 | -39.89 | 51.11 | -- | -181.75 | -128.42 | -- | -- | 0.4929 | -- | 170.26 | -- | -72.00 | -- | 69.75 | -- |
Omeros Corp | 0.00 | -179.09m | 194.69m | 198.00 | -- | -- | -- | -- | -2.90 | -1.97 | 0.00 | -1.23 | 0.00 | -- | -- | 0.00 | -35.90 | -55.51 | -44.81 | -70.10 | -- | -- | -- | -- | -- | -5.39 | 1.19 | -- | -- | -- | 3.91 | -- | -5.56 | -- |
Scilex Holding Co | 47.05m | -160.60m | 195.69m | 106.00 | -- | -- | -- | 4.16 | -1.28 | -1.28 | 0.3905 | -1.79 | 0.5307 | 5.53 | 1.92 | 448,047.60 | -121.78 | -- | -- | -- | 66.14 | -- | -229.47 | -- | 0.1356 | -12.49 | -- | -- | 22.90 | -- | -614.67 | -- | -- | -- |
Boundless Bio Inc | -100.00bn | -100.00bn | 202.96m | 72.00 | -- | -- | -- | -- | -- | -- | -- | 4.79 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.70 | -- | -- | -- |
Chromadex Corp | 83.17m | -3.53m | 208.49m | 106.00 | -- | 7.16 | -- | 2.51 | -0.047 | -0.047 | 1.11 | 0.3852 | 1.54 | 2.66 | 10.01 | 784,594.30 | -6.54 | -42.11 | -10.08 | -65.14 | 60.98 | 59.68 | -4.24 | -30.64 | 1.88 | -- | 0.0007 | -- | 15.99 | 21.50 | 70.15 | -- | -36.66 | -- |
Holder | Shares | % Held |
---|---|---|
Nantahala Capital Management LLCas of 31 Mar 2024 | 2.45m | 5.65% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 2.20m | 5.07% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 1.68m | 3.86% |
Woodline Partners LPas of 31 Mar 2024 | 1.01m | 2.33% |
683 Capital Management LLCas of 31 Mar 2024 | 800.00k | 1.84% |
Geode Capital Management LLCas of 31 Mar 2024 | 787.02k | 1.81% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 683.17k | 1.57% |
Janney Montgomery Scott LLC (Investment Management)as of 31 Mar 2024 | 660.17k | 1.52% |
The Retirement Planning Co. of New England, Inc.as of 31 Mar 2024 | 430.19k | 0.99% |
Altium Capital Management LPas of 31 Mar 2024 | 341.46k | 0.79% |